{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:25Z","timestamp":1791925405554,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.biomaterials.2022.121608","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T23:30:21Z","timestamp":1654039821000},"page":"121608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma"],"prefix":"10.1016","volume":"287","author":[{"given":"Muhammad","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianran","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pir","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaira","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-1376","authenticated-orcid":false,"given":"Bingyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biomaterials.2022.121608_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121608_bib2","doi-asserted-by":"crossref","first-page":"2100008","DOI":"10.1002\/anbr.202100008","article-title":"Nanotechnology-based strategies for early diagnosis of central nervous system disorders","volume":"1","author":"Hanif","year":"2021","journal-title":"Adv. Nanobiomed. Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121608_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bpa.12171","article-title":"International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading","volume":"24","author":"Louis","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.biomaterials.2022.121608_bib4","doi-asserted-by":"crossref","first-page":"119283","DOI":"10.1016\/j.ijpharm.2020.119283","article-title":"Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: nanomedicine approaches to improve their efficacy","volume":"581","author":"Aparicio-Blanco","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"19","key":"10.1016\/j.biomaterials.2022.121608_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"10145","key":"10.1016\/j.biomaterials.2022.121608_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","article-title":"Primary brain tumours in adults","volume":"392","author":"Lapointe","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2022.121608_bib8","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1038\/ncomms9904","article-title":"Wnt\/\u03b2-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance","volume":"6","author":"Wickstr\u00f6m","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121608_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-009-1095-5","article-title":"Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo","volume":"65","author":"Du","year":"2010","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121608_bib10","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121608_bib11","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1371\/journal.pone.0000693","article-title":"Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells","volume":"2","author":"Efferth","year":"2007","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121608_bib12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ijc.22804","article-title":"Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt\/\u03b2-catenin pathway","volume":"121","author":"Li","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121608_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/ijc.25315","article-title":"First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases","volume":"127","author":"Rasheed","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biomaterials.2022.121608_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2017.02.009","article-title":"From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy","volume":"46","author":"Efferth","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40360-018-0255-9","article-title":"Artesunate may inhibit liver fibrosis via the FAK\/Akt\/\u03b2-catenin pathway in LX-2 cells","volume":"19","author":"Lv","year":"2018","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.biomaterials.2022.121608_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbi.2017.10.011","article-title":"Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of \u03b2-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis","volume":"278","author":"Verma","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121608_bib17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121608_bib18","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-07-2970","article-title":"Artesunate derived from traditional Chinese medicine induces DNA damage and repair","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2012.03.018","article-title":"A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin","volume":"103","author":"Reichert","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121608_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/18715206113136660340","article-title":"Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines","volume":"14","author":"Karpel-Massler","year":"2014","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib22","doi-asserted-by":"crossref","first-page":"20210115","DOI":"10.1002\/EXP.20210115","article-title":"Mitochondria-targeted nanoparticles in treatment of neurodegenerative diseases","volume":"1","author":"Zhang","year":"2021","journal-title":"Exploration"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2022.121608_bib24","series-title":"Brain Co-delivery of First-Line Chemotherapy Drug and Epigenetic Bromodomain Inhibitor for Multidimensional Enhanced Synergistic Glioblastoma Therapy","first-page":"20210274","author":"Liu","year":"2022"},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121608_bib25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Therapeut."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121608_bib27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/acsnano.8b03785","article-title":"Inducing a transient increase in blood\u2013brain barrier permeability for improved liposomal drug therapy of glioblastoma multiforme","volume":"13","author":"Lundy","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2022.121608_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/EXP.20210008","article-title":"Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment","volume":"1","author":"Guo","year":"2021","journal-title":"Exploration"},{"issue":"17","key":"10.1016\/j.biomaterials.2022.121608_bib31","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.biomaterials.2014.02.031","article-title":"Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"issue":"40","key":"10.1016\/j.biomaterials.2022.121608_bib32","doi-asserted-by":"crossref","first-page":"66889","DOI":"10.18632\/oncotarget.17976","article-title":"Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment","volume":"8","author":"Belhadj","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jconrel.2012.05.014","article-title":"Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors","volume":"161","author":"Lu","year":"2012","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121608_bib34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/nnm-2016-0396","article-title":"Assembled liposomes of dual podophyllotoxin phospholipid: preparation, characterization and in vivo anticancer activity","volume":"12","author":"Ling","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biomaterials.2022.121608_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.colsurfb.2017.05.006","article-title":"Novel dual VES phospholipid self-assembled liposomes with an extremely high drug loading efficiency","volume":"156","author":"Hou","year":"2017","journal-title":"Colloids Surf., B"},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121608_bib36","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/j.bmc.2017.04.025","article-title":"Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects","volume":"25","author":"Du","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biomaterials.2022.121608_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biomaterials.2018.02.026","article-title":"Liposomes of dimeric artesunate phospholipid: a combination of dimerization and self-assembly to combat malaria","volume":"163","author":"Ismail","year":"2018","journal-title":"Biomaterials"},{"issue":"37","key":"10.1016\/j.biomaterials.2022.121608_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903277","article-title":"ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy","volume":"31","author":"Zheng","year":"2019","journal-title":"Adv. Mater."},{"issue":"24","key":"10.1016\/j.biomaterials.2022.121608_bib39","doi-asserted-by":"crossref","first-page":"2000416","DOI":"10.1002\/adma.202000416","article-title":"Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment","volume":"32","author":"Zou","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2022.121608_bib40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2022.03.036","article-title":"Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy","volume":"345","author":"Rehman","year":"2022","journal-title":"J. Contr. Release"},{"issue":"51","key":"10.1016\/j.biomaterials.2022.121608_bib41","doi-asserted-by":"crossref","first-page":"1803717","DOI":"10.1002\/adma.201803717","article-title":"Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine","volume":"30","author":"Zou","year":"2018","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121608_bib42","doi-asserted-by":"crossref","first-page":"11070","DOI":"10.1021\/acsnano.8b05265","article-title":"Apolipoprotein E peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency targeted protein therapy for glioblastoma","volume":"12","author":"Jiang","year":"2018","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121608_bib43","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1021\/acsnano.2c00320","article-title":"Brain-targeted codelivery of Bcl-2\/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy","volume":"16","author":"He","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2022.121608_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2013.09.006","article-title":"Multifunctional nanoparticles for brain tumor imaging and therapy","volume":"66","author":"Cheng","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2022.121608_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","article-title":"Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities","volume":"277","author":"Belfiore","year":"2018","journal-title":"J. Contr. Release"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121608_bib46","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acsbiomaterials.0c00743","article-title":"Effect of nanoparticle composition, size, shape, and stiffness on penetration across the blood\u2013brain barrier","volume":"6","author":"Brown","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121608_bib47","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1021\/acs.molpharmaceut.1c00500","article-title":"Dimeric artesunate\u2013phosphatidylcholine-based liposomes for Irinotecan delivery as a combination therapy approach","volume":"18","author":"He","year":"2021","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121608_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biomaterials.2022.121608_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121608_bib50","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3892\/ol.2015.3130","article-title":"NF-\u03baB inhibitor reverses temozolomide resistance in human glioma TR\/U251 cells","volume":"9","author":"Wang","year":"2015","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121608_bib51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.canlet.2010.04.013","article-title":"MiR-195, miR-455-3p and miR-10a\u2217 are implicated in acquired temozolomide resistance in glioblastoma multiforme cells","volume":"296","author":"Ujifuku","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biomaterials.2022.121608_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121608_bib53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4161\/cc.9.1.10363","article-title":"Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles","volume":"9","author":"Quiros","year":"2010","journal-title":"Cell Cycle"},{"issue":"5\u20136","key":"10.1016\/j.biomaterials.2022.121608_bib54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1387\/ijdb.041815jb","article-title":"The Wnt connection to tumorigenesis","volume":"48","author":"Behrens","year":"2004","journal-title":"Int. J. Dev. Biol."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib55","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jphs.2022.01.007","article-title":"Artesunate induces ferroptosis via modulation of p38 and ERK signaling pathway in glioblastoma cells","volume":"148","author":"Song","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biomaterials.2022.121608_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijpharm.2019.02.007","article-title":"Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug","volume":"560","author":"Ling","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2022.121608_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejps.2017.11.017","article-title":"Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties","volume":"112","author":"Lu","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121608_bib58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1166\/nnl.2019.2950","article-title":"Doxorubicin-loaded all-trans retinoic acid dimer phospholipid liposomes as co-delivery system to reverse drug resistance in breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Nanosci. Nanotechnol. Lett."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121608_bib59","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acsnano.9b08133","article-title":"Nanomaterials for nanotheranostics: tuning their properties according to disease needs","volume":"14","author":"Wong","year":"2020","journal-title":"ACS Nano"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222002484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222002484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:10:26Z","timestamp":1758906626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222002484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":59,"alternative-id":["S0142961222002484"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121608","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121608"}}